Biocartis Group NV

Biocartis Group Nv. Biocartis Group NV is a Belgium-based company, which specializes in the development of molecular diagnostic systems, especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
  • TickerA14R82
  • ISINBE0974281132
  • ExchangeEuronext Brussels
  • SectorHealth Care Equipment & Services
  • CountryBelgium

Analysts

Bart Cuypers ...
  • Cedric Duinslaeger
  • Guy Sips
  • Jan Opdecam
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Thomas Couvreur
  • Wido Jongman

Morning Note: ADYEN NA, BCART BB, EVS BB, FLUX BB, IBAB BB, IVA FP, KIN BB, NN NA, PROX BB, QRF BB, SBMO NA, VGP BB

Adyen: Issuing an upgrade Biocartis: High 4Q19 cartridge volume hopes EVS: Lower guidance for FY19 Fluxys Belgium: Christian Leclercq to become new CFO IBA: High revenue – low margin narrative continues Inventiva: 3Q19 update: Boehringer collaboration ended Kinepolis: Storing 3Q19 : content and no world cup football NN Group: Solid 3Q underlying, low divi upstream Proximus: Downgrade to REDUCE Qrf: 3Q19 results in line with estimates SBM Offshore: A well-oiled machine, increases FY guidance VGP: Positive 10M19 trading update

Bart Cuypers ...
  • Guy Sips
  • Jan Opdecam
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Wim Hoste

Morning Note: AED BB, AGFB BB, BAMNB NA, BCART BB, DSM NA, HEIJM NA, HOMI BB, INTO BB, PNL NA

Aedifica: Viking style – takeover bid HOIVA Agfa: 3Q19 preview BAM Group: Update asphalt JV proposal Biocartis: Idylla at AMP DSM: 3Q underlying EBITDA +6%, FY guidance maintained Heijmans: Update asphalt JV proposal Home Invest Belgium: Closing of aparthotel deal IO&W: 9M19 results as expected PostNL: Slight cut in estimates but see upside risk ahead

Bart Cuypers ...
  • Cedric Duinslaeger
  • Guy Sips
  • Jan Opdecam
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Thomas Couvreur
  • Wido Jongman

Morning Note: ADYEN NA, BCART BB, EVS BB, FLUX BB, IBAB BB, IVA FP, KIN BB, NN NA, PROX BB, QRF BB, SBMO NA, VGP BB

Adyen: Issuing an upgrade Biocartis: High 4Q19 cartridge volume hopes EVS: Lower guidance for FY19 Fluxys Belgium: Christian Leclercq to become new CFO IBA: High revenue – low margin narrative continues Inventiva: 3Q19 update: Boehringer collaboration ended Kinepolis: Storing 3Q19 : content and no world cup football NN Group: Solid 3Q underlying, low divi upstream Proximus: Downgrade to REDUCE Qrf: 3Q19 results in line with estimates SBM Offshore: A well-oiled machine, increases FY guidance VGP: Positive 10M19 trading update

Bart Cuypers ...
  • Guy Sips
  • Jan Opdecam
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Wim Hoste

Morning Note: AED BB, AGFB BB, BAMNB NA, BCART BB, DSM NA, HEIJM NA, HOMI BB, INTO BB, PNL NA

Aedifica: Viking style – takeover bid HOIVA Agfa: 3Q19 preview BAM Group: Update asphalt JV proposal Biocartis: Idylla at AMP DSM: 3Q underlying EBITDA +6%, FY guidance maintained Heijmans: Update asphalt JV proposal Home Invest Belgium: Closing of aparthotel deal IO&W: 9M19 results as expected PostNL: Slight cut in estimates but see upside risk ahead

Alan Vandenberghe ...
  • Cedric Duinslaeger
  • Jan Opdecam
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs
  • Thomas Couvreur
  • Wim Hoste

Morning Note: ABI BB, ADYEN NA, BEFB BB, BBED NA, BCART BB, ECONB BB, FAGR BB, FUR NA, GLPG NA, KPN NA, PROX BB, QFG BB, UMI BB

AB InBev: 3Q below expectations with more cautious outlook Adyen: Adyen signs Merlin Entertainment Befimmo: 3Q19 results in line and looking forward to FY Beter Bed Holding: Reports 6.8% growth in 3Q19 Biocartis: Liquid biopsy EGFR assay launched Econocom: 3Q update: FY guidance reiterated Fagron: Shareholder shifts read through to board level Fugro: 3Q19 results: Walking the path Galapagos: Gilead fuels 3Q19 financials KPN: Q3 result slightly better, improvement in enterprise Proximus: Q3 in line, FY19 guidance confirmed Quest for Growth: 3Q19 results Umicore: NMC cathode supply agreement wit...

Hugo Solvet

BIOCARTIS: No pain, no gain | BUY | EUR13,5(+118%)

BIOCARTIS - BUY | EUR13,5(+118%) No pain, no gain TMO deal over … a Biocartis decision What are the next steps? Expansion of menu key to drive long-term volume growth

Alan Vandenberghe ...
  • Guy Sips
  • Lenny Van Steenhuyse
  • Marcel Achterberg
  • Ruben Devos
  • Sandra Cauwenberghs

Morning Note: ASM NA, ASML NA, BESI NA, BCART BB, MELE BB, SOLB BB, VGP BB

ASM International: Hold from Buy after impressive outperformance ASML: Higher TP, Confirming our BUY-rating BE Semiconductor Industries: Upgrade to Accumulate as recovery approaches Biocartis: Additional Idylla performance studies at ESMO Melexis: TP reached: Hold from Buy Solvay: Expansion of thermoplastic composites capacity VGP: First built to suit in Zaragoza Telecom: Majority of BoD against sale of VOO to Providence Various: Removing Melexis from Dynamic Top Pick List

A director sold 10,000 shares at 14.040EUR and

A director at Biocartis Group Nv sold 10,000 shares at 14.040EUR and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The name...

An unfavourable environment weighs on BIOCARTIS, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of BIOCARTIS (BE), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date September 6, 2019, the closing price was EUR 7.20 and its target price was estimated at EUR 6.84.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Expert Corporate Governance Service (ECGS)

Biocartis - AGM 27 September 2019

On 9 May 2019, the Company issued convertible bonds for a total principal amount of EUR 150 million. The sole agenda item relates to the proposed approval and ratification, in accordance with Article 556 of the Belgian Companies Code, of conditions of the convertible bonds in case of a change of control. These are standard provisions and they are in line with the market practice. Hence, we see no reason for shareholder concern and recommend to approve.

Expert Corporate Governance Service (ECGS)

Biocartis - AGM 10 May 2019

In general, BIOCARTIS is in compliance with the Belgian regulations relating to the organisation and procedures of the Annual General Meeting.  Under ITEM 6, the board of directors seeks approval of the Company's remuneration report. Although amounts at stake are very moderate compared to sector and market practice, ECGS has concerns over the poor disclosure of the company and the lack of LTI component. Thus ECGS recommends to vote OPPOSE.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch